Burkitt Lymphoma Clinical Trials

19 studies are recruiting for burkitt lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

   Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastom…

   Stage

   Phase 1

   Ages

   0 to 25

   Site

   Children's Hospital Los Angeles ( Site 1006), Los Angeles, California

   Locations

   71 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06395103 on ClinicalTrials.gov

2. Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

   Background: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venetoclax, ibrutinib, prednisone, obinutuzumab, and le…

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03223610 on ClinicalTrials.gov

3. Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

   Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV in the United States. People with HIV are up to 17 times more likely to get NHL than people who do not have HIV. The disease may also be different in these two groups. More study is needed for treating peo…

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05389423 on ClinicalTrials.gov

4. AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

   This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas. All evaluable participants will be followed for overall survival (OS), progression free survival (PFS), and …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford University, Palo Alto, California

   Run by

   Stanford University

   See if you can join NCT06340737 on ClinicalTrials.gov

5. LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

   This is a phase I, interventional, single arm, open label, treatment study designed to evaluate the safety and efficacy of LV20.19 CAR -T cells with pirtobrutinib bridging and maintenance in adult patients with B cell malignancies that have failed prior therapies.

   Stage

   Phase 1

   Ages

   18 to 81

   Site

   Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin

   Run by

   Medical College of Wisconsin

   See if you can join NCT05990465 on ClinicalTrials.gov

6. Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

   This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.

   Stage

   Phase 1

   Ages

   13 to 90

   Site

   City of Hope, Duarte, California

   Locations

   11 in total

   Run by

   Vironexis Biotherapeutics Inc.

   See if you can join NCT06533579 on ClinicalTrials.gov

7. Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

   This phase Ib/II trial tests the safety, side effects, best dose and how well giving CX-5461 works for the treatment of patients with B-cell non-Hodgkin lymphoma. CX-5461 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CX-5461 may be safe, tolerabl…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California

   Locations

   8 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07069699 on ClinicalTrials.gov

8. CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

   The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is effective in preventing GVHD, but immune reconst…

   Stage

   Not phased

   Ages

   Up to 25

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Run by

   Children's Hospital of Philadelphia

   See if you can join NCT03810196 on ClinicalTrials.gov

9. Allo HSCT Using RIC and PTCy for Hematological Diseases

   This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamid…

   Stage

   Phase 2

   Ages

   Up to 75

   Site

   Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

   Run by

   Masonic Cancer Center, University of Minnesota

   See if you can join NCT05805605 on ClinicalTrials.gov

10. Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

    This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVH…

    Stage

    Phase 2

    Ages

    Up to 60

    Site

    Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

    Run by

    Masonic Cancer Center, University of Minnesota

    See if you can join NCT03314974 on ClinicalTrials.gov

11. Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

    This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    C. Babis Andreadis

    See if you can join NCT04545762 on ClinicalTrials.gov

12. Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

    The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, n…

    Stage

    Not phased

    Ages

    0 to 38

    Site

    Children's Hospital Colorado, Aurora, Colorado

    Locations

    5 in total

    Run by

    Children's Hospital Medical Center, Cincinnati

    See if you can join NCT06131801 on ClinicalTrials.gov

13. Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

    This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth …

    Stage

    Phase 2

    Ages

    0 and older

    Site

    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

    Run by

    Fred Hutchinson Cancer Center

    See if you can join NCT04195633 on ClinicalTrials.gov

14. MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

    This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion with individualized ALC-based dosing of ATG to stud…

    Stage

    Not phased

    Ages

    0 to 25

    Site

    Children's Wisconsin, Milwaukee, Wisconsin

    Run by

    Medical College of Wisconsin

    See if you can join NCT05794880 on ClinicalTrials.gov

15. Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

    This phase II trial tests the safety, best dose, and effectiveness of epcoritamab when given with etoposide, cyclophosphamide, vincristine, doxorubicin, prednisone and rituximab (EPOCH-R) for the treatment of patients with aggressive B-cell non-Hodgkin lymphoma. Epcoritamab is a bispecific antibody…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

    Run by

    University of Washington

    See if you can join NCT07097363 on ClinicalTrials.gov

16. Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

    Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzumab Vedotin once every 21 days until they receive…

    Stage

    Phase 1

    Ages

    12 to 70

    Site

    New York Medical Center, Valhalla, New York

    Run by

    New York Medical College

    See if you can join NCT04491370 on ClinicalTrials.gov

17. Study of SGR-1505 in Mature B-Cell Neoplasms

    The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Banner Health - MD Anderson Cancer Center, Gilbert, Arizona

    Locations

    36 in total

    Run by

    Schrödinger, Inc.

    See if you can join NCT05544019 on ClinicalTrials.gov

18. Long-term Follow-up Study of Patients Receiving CAR-T Cells

    This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following: Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refracto…

    Stage

    Not phased

    Ages

    18 to 80

    Site

    Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin

    Run by

    Medical College of Wisconsin

    See if you can join NCT03375619 on ClinicalTrials.gov

19. Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

    The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relap…

    Stage

    Phase 2

    Ages

    3 to 31

    Site

    New York Medical College, Valhalla, New York

    Run by

    New York Medical College

    See if you can join NCT02393157 on ClinicalTrials.gov